Aukera Therapeutics has raised CHF 4.5m (EUR 4.76m), bringing Zürcher Kantonalbank and seasoned biotech operator David Urech into an early-stage AI-enabled mTORC1 programme—an unusual show of risk appetite in today’s funding market.